Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BHC, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Rifaximin FDA approved May 2004 · Xifaxan |
Pouchitis | Phase 4 · NCT06312683 | Recruiting |
| Perfluorohexyloctane FDA approved May 2023 · Miebo |
Dry Eye | Phase 4 · NCT06346340 | Completed |
| Bupropion Hydrobromide FDA approved Apr 2008 · Aplenzin |
Major Depressive Disorder | Phase 4 · NCT02129751 | Not yet recruiting |
| Halobetasol Propionate And Tazarotene FDA approved Apr 2019 · Duobrii |
Acne Keloidalis Nuchae | Phase 3 · NCT05608499 | Terminated |
| Lifitegrast FDA approved Jul 2016 · Xiidra |
Dry Eye Disease | Phase 3 · NCT07111013 | Withdrawn |
| Halobetasol Propionate FDA approved Nov 2018 · Bryhali |
Acne Keloidalis Nuchae | Phase 3 · NCT05608499 | Terminated |
| Plecanatide FDA approved Jan 2017 · Trulance |
Functional Constipation (FC) | Phase 2 · NCT07723924 | Active not recruiting |
| Brodalumab FDA approved Feb 2017 · Siliq |
Breast Cancer | Phase 1 · NCT06673329 | Recruiting |
| Clindamycin FDA approved Nov 2000 · Clindagel |
Acne | Early Phase 1 · NCT05582434 | Active not recruiting |
| (Xiidra®) Lifitegrast Ophthalmic Solutio | Ocular Surface Disease | Phase 4 · NCT07490535 | Not yet recruiting |
| Perfluorohexyloctane ophthalmic solution | Dry Eye | Phase 4 · NCT07054606 | Completed |
| Miebo four times per day | Dry Eye Syndrome (DES) | Phase 4 · NCT07650708 | Recruiting |
| IDP-118 Lotion | Psoriasis | Phase 4 · NCT03988439 | Completed |
| Determine the ability of the TearScience | Dry Eye | Phase 4 · NCT07722624 | Active not recruiting |
| CABTREO is a fixed-combination product o | Acne Vulgaris | Phase 4 · NCT07524946 | Recruiting |
| Determine the ability of the iTrace™, BO | Dry Eye | Phase 4 · NCT07790211 | Recruiting |
Also used in these trials (approved or third-party drugs, not BHC's own candidates): Adapalene And Benzoyl Peroxide, Clindamycin Phosphate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BHC holds $1.8B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BHC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| John Paulson Director |
Insider | 73,686,111 | 19.70% | 2026-06-30 |
| PAULSON & CO. INC. 10% owner |
Insider | 73,255,869 | 19.59% | 2025-11-25 |
| Alex Meruelo | 5%+ holder (13D) | 36,761,788 | 9.83% | 2025-03-31 |
| Icahn Capital LP | 5%+ holder (13D) | 34,721,118 | 9.28% | 2025-05-20 |
| Goldentree Asset Management LP | Institution (13F) | 34,665,731 | 9.27% | 2026-06-30 |
| Royal Bank of Canada | Institution (13F) | 10,832,582 | 2.90% | 2026-06-30 |
| Healthcare of Ontario Pension Plan Trust | Institution (13F) | 8,000,000 | 2.14% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 7,465,468 | 2.00% | 2026-06-30 |
| Goldman Sachs Group Inc | Institution (13F) | 6,225,131 | 1.66% | 2026-06-30 |
| MFN Partners Management, LP | Institution (13F) | 6,000,000 | 1.60% | 2026-06-30 |
| SG Americas Securities, LLC | Institution (13F) | 5,535,771 | 1.48% | 2026-06-30 |
| Acadian Asset Management. LLC | Institution (13F) | 5,482,986 | 1.47% | 2026-06-30 |
Share count 373,990,561 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-19 filed 2026-08-20 |
Lenar Aimee J. |
Sale (S) | 36,827 | $7.03 | 334,853 |
| 2026-07-17 filed 2026-07-20 |
Lenar Aimee J. |
Tax withholding (F) | 5,260 | $4.83 | 371,680 |
| 2026-07-15 filed 2026-07-17 |
Lenar Aimee J. |
Tax withholding (F) | 23,395 | $4.89 | 376,940 |
| 2026-07-14 filed 2026-07-15 |
LEE STEVEN HYOSIG |
Tax withholding (F) | 3,125 | $4.75 | 70,114 |
| 2026-06-30 filed 2026-07-02 |
WECHSLER AMY B |
Award (A) | 1,394 | $4.93 | 314,979 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BHC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →